#USA #Chicago #Prader-Willi Syndrome #Sedogen #Diazoxide

Sedogen Secures New Patent for Diazoxide Formulations in Treating Prader-Willi Syndrome

Sedogen LLC, a dedicated biopharmaceutical company, has made an announcement that brings hope to many affected by Prader-Willi Syndrome (PWS). On April 15, 2026, the company revealed the issuance of a new patent from the U.S. Patent and Trademark Office, specifically patent number 12,589,098. This crucial patent pertains to the application of pharmaceutical formulations of diazoxide aimed at reducing behavioral symptoms associated with PWS.

Understanding Prader-Willi Syndrome

Prader-Willi Syndrome is a rare genetic disorder that occurs in approximately 1 in 16,000 births. It results from the loss of function of specific genes on chromosome 15q11-q13, with features that pose numerous challenges to affected individuals and their families. The symptoms often include developmental delays, intellectual disabilities, and particularly notable are the food-related behavioral symptoms. Individuals with PWS might experience an incessant preoccupation with food, leading to hyperphagia, which is characterized by an insatiable hunger that can put them at risk for serious health issues.

Significance of the Patent

The newly issued patent is a significant milestone for Sedogen. Sara Cotter, the founder and president of the company, expressed her personal connection and commitment to this cause. Her journey began in 2013 when her daughter was the first individual diagnosed with PWS to receive diazoxide treatment. Cotter’s personal testimony underscores the importance of this patent, as it represents years of effort and dedication towards improving treatment options for the PWS community. The patent is valid until June 6, 2034, marking a period during which Sedogen can further develop and commercialize its diazoxide formulations.

Looking Forward

Sedogen’s efforts are not just about a product or a patent; they are about making a genuine difference in the lives of individuals and families affected by this challenging syndrome. The company is poised to take active steps towards not only bringing this medication to the market but also ensuring that it is accessible to those in need. Additionally, with ongoing research and collaboration with organizations such as the Foundation for Prader-Willi Research and the Prader-Willi Syndrome Association, Sedogen is focused on enhancing its understanding of the disorder and contributing positively to the community.

In summary, the issuance of this patent marks a new chapter in the treatment of behavioral symptoms in Prader-Willi Syndrome. As Sedogen continues to pave the way for innovative therapies, the future looks promising for families and individuals grappling with the challenges posed by PWS. The therapeutic potential of diazoxide could eventually lead to better management of the condition, providing relief and hope for a better quality of life.

For further details about PWS and ongoing research, interested parties are encouraged to visit the websites of the Foundation for Prader-Willi Research (www.fpwr.org) or the Prader-Willi Syndrome Association (www.pwsausa.org). Sedogen’s commitment to this cause is evident, and through continued support and innovation, brighter days are ahead for those impacted by this syndrome.